Influenza Human Challenge Model
NCT05332899 is a phase 1 interventional trial sponsored by Emory University. As of 21 Nov 2026, it is recruiting participants. It studies Influenza Virus Type A H3N2 Challenge in Influenza. The registry lists an enrollment of 80 participants at 2 sites in 1 country. The registry lists a start date of 24 May 2022 and a primary completion date of 31 Dec 2027. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05332899 |
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Emory University |
| Enrollment | 80 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Influenza |
| Drugs | Influenza Virus Type A H3N2 Challenge |
| Start | 24 May 2022 |
| Primary completion | 31 Dec 2027 |
| Study completion | 31 Dec 2027 |
| Last update posted | 27 Mar 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Recruiting
- Recruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05332899
Each answer restates registry values shown on this page.
What is NCT05332899?
NCT05332899 is a phase 1 interventional trial sponsored by Emory University. It studies Influenza Virus Type A H3N2 Challenge in Influenza.
Is NCT05332899 recruiting?
As of 21 Nov 2026, it is recruiting participants. 2 of its 2 sites list their own status as recruiting.
Who leads NCT05332899?
The registry names Nadine Rouphael, MD (principal investigator, Emory University) as the overall official.
Where does NCT05332899 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT05332899 study?
The registered drug and biological interventions are Influenza Virus Type A H3N2 Challenge.
When is NCT05332899 expected to complete?
The registry lists a primary completion date of 31 Dec 2027 and a study completion date of 31 Dec 2027. The sponsor last updated the record on 27 Mar 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.